157
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia

, , , , , , , , , , , , , & show all
Pages 1274-1280 | Received 17 Apr 2013, Accepted 14 Aug 2013, Published online: 03 Oct 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Koen van Besien & Richard R. Furman. (2014) To the end of chronic lymphocytic leukemia: what should be the role of allogeneic transplant?. Leukemia & Lymphoma 55:6, pages 1221-1222.
Read now

Articles from other publishers (3)

Robert Puckrin, Mona Shafey & Jan Storek. (2023) The role of allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: A review. Frontiers in Oncology 12.
Crossref
Da-Yong Huang, Yi-Fei Hu, Na Wei, Li Fu, Lin Wu, Jing Shen, Jing-Shi Wang & Zhao Wang. (2019) Innovative analysis of predictors for overall survival from systemic non-Hodgkin T cell lymphoma using quantile regression analysis. Chinese Medical Journal 132:3, pages 294-301.
Crossref
C. Shustik, I. Bence-Bruckler, R. Delage, C. J. Owen, C. L. Toze & S. Coutre. (2017) Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Annals of Hematology 96:7, pages 1185-1196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.